Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series

BMC Research Notes

Florenzo Iannone²  Fulvio Moramarco³  Antonella Meini⁴  Barbara Teruzzi¹  Marco Cattalini⁴  Francesco La Torre³ 

[1] Rheumatology Unit, L. Sacco University Hospital, Milan, Italy;Policlinic Hospital, Rheumatology Unit, University of Bari, Bari, Italy;Department of Paediatrics, Antonio Perrino Hospital, Brindisi, Italy;Pediatric Clinic University of Brescia and Spedali Civili di Brescia, Brescia, Italy

关键词: Uveitis;    Children;    Juvenile idiopathic arthritis;    Adalimumab;   

Others  :  1132696
DOI  :  10.1186/1756-0500-7-316

 received in 2014-03-18, accepted in 2014-05-14,  发布年份 2014

【 摘 要 】

Background

Juvenile idiopathic arthritis is a relatively common chronic disease of childhood, and is associated with persistent morbidity and extra-articular complications, one of the most common being uveitis. The introduction of biologic therapies, particularly those blocking the inflammatory mediator tumor necrosis factor-α, provided a new treatment option for juvenile idiopathic arthritis patients who were refractory to standard therapy such as non-steroidal anti-inflammatory drugs, corticosteroids and/or methotrexate.

Case presentations

The first case was a 2-year-old girl with juvenile idiopathic arthritis and uveitis who failed to respond to treatment with anti-inflammatories, low-dose corticosteroids and methotrexate, and had growth retardation. Adalimumab 24 mg/m² every 2 weeks and prednisone 0.5 mg/kg/day were added to methotrexate therapy; steroid tapering and withdrawal started after 1 month. After 2 months the patient showed good control of articular and ocular manifestations, and she remained in remission for 1 year, receiving adalimumab and methotrexate with no side effects, and showing significant improvement in growth. Case 2 was a 9-year-old boy with an 8-year history of juvenile idiopathic arthritis and uveitis that initially responded to infliximab, but relapse occurred after 2 years off therapy. After switching to adalimumab, and adjusting doses of both adalimumab and methotrexate based on body surface area, the patient showed good response and corticosteroids were tapered and withdrawn after 6 months; the patient remained in remission taking adalimumab and methotrexate. The final case was a 5-year-old girl with juvenile idiopathic arthritis for whom adalimumab was added to methotrexate therapy after three flares of uveitis. The patient had two subsequent episodes of uveitis that responded well to local therapy, but was then free of both juvenile idiopathic arthritis and uveitis symptoms, allowing methotrexate and then adalimumab to be stopped; the patient remained in drug-free remission.

Conclusion

This report includes the first published case of the use of adalimumab in a child aged <3 years. Our clinical experience further supports the use of biologic therapy for the management of juvenile idiopathic arthritis and uveitis in children as young as two years of age.

【 授权许可】

   
2014 La Torre et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:390-392.
• [2]Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998, 25(10):1991-1994.
• [3]Ravelli A, Marini A: Juvenile idiopathic arthritis. Lancet 2007, 369(9563):767-778.
• [4]Borchers AT, Selmi C, Cheema G, Keen CL, Shoeneld Y, Gershwin ME: Juvenile idiopathic arthritis. Autoimmun Rev 2006, 5:279-298.
• [5]Gaspari S, Marcovecchio ML, Breda L, Chiarelli F: Growth in juvenile idiopathic arthritis: the role of inflammation. Clin Exp Rheumatol 2011, 29(1):104-110.
• [6]Petty RE, Cassidy JT: Chronic arthritis in childhood. In Textbook of Pediatric Rheumatology. 6th edition. Philadelphia: W.B. Saunders; 2011:211-235.
• [7]Ruperto N, Murray KJ, Gerloni V, Wilffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A, Pediatric Rheumatology International Trials Organization: A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004, 50(7):2191-2201.
• [8]Beresord MW, Baildam EM: New advances in the management of juvenile idiopathic arthritis: II. The era of biological. Arch Dis Child Educ Pract Ed 2009, 94(5):151-156.
• [9]Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM: The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systemic review. Semin Arthritis Rheum 2013, 42:597-618.
• [10]Boiu S, Marniga E, Bader-Meunier B, Mouy R, Compeyrot-Lacassagne S, Quartier P, Wouters CH: Functional status in severe juvenile idiopathic arthritis in the biologic treatment era: an assessment in a French paediatric rheumatology referral centre. Rheumatology 2012, 51(7):1285-1292.
• [11]Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N: 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutics agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011, 63(4):465-482.
• [12]Murray PI, Sivaraj RR: Anti-TNF-alpha therapy for uveitis: Behçet and beyond. Eye 2005, 19:831-838.
• [13]Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Gómez Vidal MA, Collantes-Estévez E, RamírezChamond R, Omar M: Aqueous humor and serum tumour necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001, 33:251-255.
• [14]Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estévez E: Tumour necrosis factor-alpha levels in aqueous humor and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 2004, 20:155-157.
• [15]Thorne JE, Woreta FA, Dunne JP, Jabs DA: Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010, 117(7):1436-1441.
• [16]Marvillet I, Terrada C, Quartier P, Quoc EB, Bodaghi B, Prieur AM: Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine 2009, 76:383-388.
• [17]Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, Tessler HH, Nussenblatt RB, Rosenbaum JT, Reed GF, Vitale S, Smith JR, Goldstein DA: Epidemiology and course of disease in childhood uveitis. Ophthalmology 2009, 116:1544-1551. e1
• [18]Kanski JJ: Uveitis in juvenile chronic arthritis: incidence, clinical features and prognosis. Eye (Lond) 1988, 2:641-645.
• [19]Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, Silverman ED: Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term follow-up study. Arthritis Rheum 2007, 56:647-657.
• [20]Chia A, Lee V, Graham EM, Edelsten C: Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol 2003, 135:757-762.
• [21]Holland GN, Denove CS, Yu F: Chronic anterior uveitis in children: clinical characteristics and complications. Am J Ophthalmol 2009, 147:667-678. e5
• [22]Woreta F, Thorne JE, Jabs DA, Kedhar SR, Dunn JP: Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2007, 143:647-655.
• [23]Edelsten C, Lee V, Bentley CR, Kanski JJ, Graham EM: An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol 2002, 86:51-56.
• [24]Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA: Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol 2007, 143:840-846.
• [25]Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, et al.: Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008, 359(8):810-820.
• [26]Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, et al.: A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007, 56:3096-3106.
• [27]Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763-769.
• [28]Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M: Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007, 91(3):319-324.
• [29]Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A: Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol 2011, 31(2):165-173.
• [30]Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK: Tumor necrosis factor-α blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007, 34:1146-1150.
• [31]Tynjala P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V: Adalimumab in juvenile idiopathic arthritis associated chronic anterior uveitis. Rheumatology 2008, 47:339-344.
• [32]Vazquez-Cobian LB, Flynn T, Lehman TJ: Adalimumab therapy for childhood uveitis. J Pediatr 2006, 149(4):572-575.
• [33]Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF: Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012, 119(8):1575-1581.
• [34]Kotaniemi K, Säilä H, Kautiainen H: Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 2011, 5:1425-1429.
• [35]Magli A, Forte R, Navarro P, Russo G, Orlando F, Latanza L, Alessio M: Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2013, 251(6):1601-1606.
• [36]Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S, Bresci C, Lorusso M, Lepore L, Cimaz R: Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 2011, 63(4):612-618.
• [37]Simonini G, Taddio A, Cattalini M, Caputo R, de Libero C, Parentin F, Pagnini I, Lepore L, Cimaz R: Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol 2013, 11(1):16. BioMed Central Full Text
• [38]Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, Bracaglia C, Shardlow A, Parentin F, Cimaz R, Simonini G, Falcini F, Corona F, Viola S, De Marco R, Breda L, La Torre F, Vittadello F, Martini G, Zulian F: Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow-up data from the Italian Registry. J Rheumatol 2013, 40(1):74-79.
• [39]Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW: Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis 2013, 72(11):1806-1812.
• [40]Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, Kimura Y, CARRA Registry Investigators: Disease-modifying anti-rheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 2012, 39(9):1867-1874.
• [41]Schmeling H, Horneff G: Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005, 44:1008-1011.
• [42]Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS: A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53:18-23.
• [43]Taban M, Dupps WJ Jr, Mandell B, Perez VL: Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006, 14:145-150.
• [44]Braun J, Baraliakos X, Listing J, Sieoer J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447-2451.
• [45]Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, Feldman BM, Laxer RM, Schneider R, Silverman ED: Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006, 45:982-989.
• [46]Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A: Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010, 62(8):2517-2524.
• [47]Beresford MW: Juvenile idiopathic arthritis. New insights into classification, measures of outcome, and pharmaco-therapy. Pediatr Drugs 2011, 13(3):161-173.